DE59010941D1
(de)
|
1989-04-21 |
2005-03-24 |
Amgen Inc |
TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
|
US6221675B1
(en)
|
1989-04-21 |
2001-04-24 |
Amgen, Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
CA2133326C
(en)
*
|
1992-03-30 |
2005-03-01 |
Craig A. Smith |
Fusion proteins comprising tumor necrosis factor receptor
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
CA2195665A1
(en)
*
|
1994-07-22 |
1996-02-08 |
Robert Frederick Geoffrey Booth |
Pharmaceutical compositions comprising a chimaeric tnf binding protein
|
US7091181B2
(en)
|
1994-12-12 |
2006-08-15 |
Omeros Corporation |
Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
|
AU4658596A
(en)
*
|
1995-02-03 |
1996-08-21 |
G.D. Searle & Co. |
Novel c-mpl ligands
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
US5705364A
(en)
*
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US5721121A
(en)
*
|
1995-06-06 |
1998-02-24 |
Genentech, Inc. |
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
|
US6656466B1
(en)
|
1995-06-06 |
2003-12-02 |
Genetech, Inc. |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
|
US7012060B1
(en)
|
1995-07-14 |
2006-03-14 |
Applied Research Systems Ars Holding N.V. |
TNF receptor and steroid hormone in a combined therapy
|
AU715260B2
(en)
|
1995-07-14 |
2000-01-20 |
Laboratoires Serono Sa |
TNF receptor and steroid hormone in a combined therapy
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
HRP970224A2
(en)
*
|
1996-05-08 |
1998-04-30 |
Hoffmann La Roche |
TREATMENT OF ASTHMA WITH TNFR-Ig
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
EP0942740B1
(en)
|
1996-12-06 |
2003-08-27 |
Amgen Inc., |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
SI0942740T1
(en)
*
|
1996-12-06 |
2003-12-31 |
Amgen Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
EP1170017A1
(en)
*
|
1997-05-12 |
2002-01-09 |
The Kennedy Institute Of Rheumatology |
Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
|
WO1999003998A1
(en)
*
|
1997-07-17 |
1999-01-28 |
The Regents Of The University Of Michigan |
Methods and compositions for tumor reduction
|
EP1097165A4
(en)
*
|
1998-07-13 |
2001-09-12 |
Parkash S Gill |
NEW INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH
|
US7067144B2
(en)
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU1345000A
(en)
*
|
1998-11-05 |
2000-05-22 |
Omeros Medical Systems, Inc. |
Irrigation solution and method for inhibition of pain and inflammation
|
TR200504220T2
(tr)
|
1998-12-17 |
2007-04-24 |
Biogen Idec Ma Inc. |
Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
|
IL127851A0
(en)
*
|
1998-12-30 |
1999-10-28 |
Applied Research Systems |
Inhibition of TNF activity
|
EP1022027A1
(en)
*
|
1999-01-22 |
2000-07-26 |
Applied Research Systems ARS Holding N.V. |
Tumor necrosis factor antagonists and their use in endometriosis
|
AU763575B2
(en)
*
|
1999-04-02 |
2003-07-24 |
Immunex Corporation |
Use of soluble tumor necrosis factor receptor for treatment heart failure
|
WO2000073481A1
(en)
*
|
1999-05-28 |
2000-12-07 |
Targeted Genetics Corporation |
Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
|
EP1939300A1
(en)
*
|
1999-05-28 |
2008-07-02 |
Targeted Genetics Corporation |
Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
US6627199B1
(en)
|
1999-07-09 |
2003-09-30 |
Amgen Inc |
Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
|
CA2689694A1
(en)
*
|
1999-07-21 |
2001-02-01 |
Omeros Corporation |
Solutions and methods for inhibition of pain, inflammation and cartilage degradation
|
EP1210435A1
(en)
|
1999-08-04 |
2002-06-05 |
Amgen Inc. |
Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
|
AU6517800A
(en)
|
1999-08-04 |
2001-03-05 |
Amgen, Inc. |
Ntr3, a member of the tnf-receptor supergene family
|
GB9927681D0
(en)
*
|
1999-11-23 |
2000-01-19 |
Glaxo Group Ltd |
Protein
|
EP1282699B1
(en)
|
2000-05-04 |
2012-11-21 |
Sarepta Therapeutics, Inc. |
Splice-region antisense composition and method
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
CN102755646A
(zh)
|
2002-07-19 |
2012-10-31 |
艾博特生物技术有限公司 |
TNF α相关疾病的治疗
|
BR0313491A
(pt)
*
|
2002-08-16 |
2007-08-14 |
Wyeth Corp |
composições e métodos para tratar distúrbios associados ao rage
|
AU2003258388C1
(en)
*
|
2002-09-13 |
2010-03-18 |
The University Of Queensland |
Gene expression system based on codon translation efficiency
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
WO2004075918A1
(en)
|
2003-02-28 |
2004-09-10 |
Ares Trading S.A. |
Liquid formulations of tumor necrosis factor-binding proteins
|
CA2542046A1
(en)
*
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
BRPI0517837A
(pt)
*
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
AU2006230419A1
(en)
*
|
2005-03-31 |
2006-10-05 |
Targeted Genetics Corporation |
Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
TWI424161B
(zh)
|
2005-11-01 |
2014-01-21 |
Abbvie Biotechnology Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
US7785834B2
(en)
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
EP2089521A1
(en)
*
|
2006-02-08 |
2009-08-19 |
Ercole Biotech, Inc. |
Soluble tnf receptors and their use in treatment of disease
|
WO2007109686A2
(en)
|
2006-03-20 |
2007-09-27 |
University Of Pittsburgh |
Immunomodulation of inflammatory conditions utilizing follistatin-like protein-1 and agents that bind thereto
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
EP3088410A3
(en)
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
EP2043711A4
(en)
|
2006-06-30 |
2017-08-30 |
AbbVie Biotechnology Ltd |
Automatic injection device
|
JP2010501622A
(ja)
*
|
2006-08-28 |
2010-01-21 |
アレス トレーディング ソシエテ アノニム |
Fc−融合タンパク質の精製法
|
FI2061803T4
(fi)
|
2006-08-28 |
2023-03-14 |
|
Process for the purification of fc-containing proteins
|
EA017733B1
(ru)
*
|
2006-08-28 |
2013-02-28 |
Арес Трейдинг С.А. |
СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
US8338376B2
(en)
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
WO2008049053A2
(en)
|
2006-10-20 |
2008-04-24 |
Biogen Idec Ma Inc. |
Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
|
EP2165194A4
(en)
|
2007-05-31 |
2010-09-08 |
Abbott Lab |
BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
KR101595634B1
(ko)
|
2007-06-14 |
2016-02-18 |
갈락티카 파마슈티칼스, 인크. |
Rage 융합 단백질
|
EP2072527A1
(en)
|
2007-12-21 |
2009-06-24 |
Altonabiotec AG |
Fusion polypeptides comprising a SHBG dimerization component and uses thereof
|
US8658379B2
(en)
|
2008-01-29 |
2014-02-25 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Follistatin-like protein-1 as a biomarker for sepsis
|
AU2009280913A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Avesthagen Limited |
An expression vector and a method thereof
|
BRPI0923806A2
(pt)
|
2008-12-30 |
2015-07-14 |
Centocor Ortho Biotech Inc |
Marcadores séricos para previsão da resposta clínica a anticorpos anti-tnfa em pacientes com espondilite anquilosante
|
WO2010127146A1
(en)
|
2009-04-29 |
2010-11-04 |
Abbott Biotechnology Ltd |
Automatic injection device
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
US8722615B2
(en)
|
2009-12-02 |
2014-05-13 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life
|
US20110150891A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
PE20121691A1
(es)
|
2010-01-15 |
2012-12-14 |
Kirin Amgen Inc |
Formulacion de anticuerpos y regimenes terapeuticos
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
JP5809242B2
(ja)
|
2010-04-21 |
2015-11-10 |
アッヴィ バイオテクノロジー リミテッド |
治療薬の制御送達のための装着型自動注入装置
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
HUE039740T2
(hu)
|
2010-06-03 |
2019-01-28 |
Abbvie Biotechnology Ltd |
Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
|
FR2962335B1
(fr)
|
2010-07-12 |
2013-01-18 |
Cll Pharma |
Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
|
WO2012019099A2
(en)
|
2010-08-05 |
2012-02-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Follistatin-like-protein-1 as a biomarker for inflammatory disorders
|
EP2667918B1
(en)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
WO2012129174A1
(en)
|
2011-03-18 |
2012-09-27 |
Abbott Laboratories |
Systems. devices and methods for assembling automatic injection devices and sub-asseblies thereof
|
WO2012135524A1
(en)
|
2011-03-29 |
2012-10-04 |
Abbott Laboratories |
Improved shroud deployment in automatic injection devices
|
WO2012145752A2
(en)
|
2011-04-21 |
2012-10-26 |
Abbott Laboratories |
Wearable automatic injection device for controlled administration of therapeutic agents
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
WO2012170938A1
(en)
|
2011-06-08 |
2012-12-13 |
Acceleron Pharma Inc. |
Compositions and methods for increasing serum half-life
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
EA028520B1
(ru)
|
2011-10-18 |
2017-11-30 |
Кохерус Байосайенсис, Инк. |
Препараты этанерцепта, стабилизированные меглюмином
|
KR101525919B1
(ko)
*
|
2012-05-11 |
2015-06-03 |
가톨릭대학교 산학협력단 |
자가면역 질환 예방 및 치료를 위한 tnfr2를 기반으로 하는 이중 항체
|
CN104902914B
(zh)
|
2012-09-11 |
2019-01-01 |
科荣生生物科学公司 |
高纯度和优异产量的正确折叠的依那西普
|
EP3126392B1
(en)
|
2014-03-31 |
2019-09-11 |
Kirin-Amgen, Inc. |
Methods of treating nail and scalp psoriasis
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
CA2970577A1
(en)
|
2014-12-22 |
2016-06-30 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
EP3440113A1
(en)
|
2016-04-08 |
2019-02-13 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
BR112019011689A2
(pt)
|
2016-12-14 |
2019-10-22 |
Progenity Inc |
tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
WO2020010118A1
(en)
|
2018-07-03 |
2020-01-09 |
Novartis Inflammasome Research, Inc. |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
WO2020047029A1
(en)
|
2018-08-29 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
MX2021009242A
(es)
|
2019-01-31 |
2021-10-26 |
Sanofi Biotechnology |
Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica.
|
CN110964119A
(zh)
*
|
2019-12-05 |
2020-04-07 |
沣潮医药科技(上海)有限公司 |
抗疟二聚体免疫粘附素、药物组合物和用途
|
CN117440967A
(zh)
|
2020-12-09 |
2024-01-23 |
怡诺安有限公司 |
抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途
|